ArticleCell biochemistry and biophysics2026
In-silico Exploration of the Possible Prolactin Pathway Related Targets of B. Monnieri against Triple Negative Breast Cancer: Selection of the Best Target Ligand Combination.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacopa monnieri (B. monnieri) or Bramhi is a widely available herb traditionally used in Ayurvedic and Siddha medicine for improvements in neuroprotective and cognitive capabilities in humans, with some evidence accumulating with respect to its anticancer potential. Despite the availability of pre-clinical data in terms of its in-vitro anti TNBC potential, a systematic in-silico analysis in terms of the binding behaviour of B. monnieri bioactive principles, to certain signal transduction pathway-related targets is clearly lacking. Triple Negative Breast Cancer (TNBC) is one of the most aggressive types of Breast Cancer (BC) and a significant percentage of such cases express the Prolactin signalling pathway (despite being negative for progesterone, estrogen and human epidermal growth factor receptor 2 (HER2)). This aspect provided us with opportunities for the identification or validation of druggable targets and the screening and selection of the best candidate using a combination of in-silico tools. Specifically, the aim of this study was to examine proteins involved in the prolactin-based signalling system to determine the optimum drug-target combination. A combination of network pharmacology, docking, drug likeliness determination, and molecular dynamic simulation approaches, using widely accepted in-silico tools were employed for the identification of the best drug-target combination. Based on our defined in-silico flow, we found Luteolin (286.24 g/mol) and Wogonin (284.26 g/mol) were good candidates and they met oral delivery criteria. This finding provided in silico evidence for these bioactive molecules to possibly be candidate drugs for TNBC therapy by decreasing stemness, increasing apoptosis and differentiation.Hence, this novel finding provides an opportunity for the experimenter to further verify its therapeutic potential in a battery of in-vitro and in-vivo pre-clinical tests in terms of their cell death and/or differentiation induction capabilities.
Indexed as
Identifiers
41533315What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.